Guide to Selecting Vendors for Patient Support Programs
Learn how to evaluate and select the right partners for your patient support programs. This…
Certara2025 年 10 月 20 日
U.S. International Reference Pricing: Global Implications and Pharma Strategy
Unintended global fallout of international reference pricing: How the U.S. Most Favored Nation policy could…
Certara2025 年 10 月 6 日
‘Most Favored Nation’ Policy Could Have Profound Impact on Global Drug Pricing if Fully Implemented
Editor’s Note: Jiwon Oh provided research support for this article. She is a Certara Market…
Certara2025 年 5 月 23 日
Everything you need to know about ILAP 2.0
This white paper share’s key insights on the relaunch of MHRA’s Innovative Licensing and Access…
Certara2025 年 5 月 19 日
Joint Clinical Assessment (JCA) And Potential Consequences For The Evaluation Of Gene Therapies
In October 2019, Galderma announced that the U.S. FDA approved AKLIEF® (trifarotene) Cream, 0.005% for the…
Certara2024 年 6 月 17 日
Accelerating a drug launch with value communication technology and an integrated workflow
With early approvals for a targeted cancer drug in Brazil and Argentina, this global pharmaceutical…
Certara2023 年 10 月 2 日
Using customer engagement technology to create value communication tools for ABILIFY MAINTENA® (aripiprazole)
Otsuka identified several weaknesses in their existing workflow for developing value communication tools. In particular,…
Certara2023 年 10 月 2 日
Using Real-World Evidence to Derive an External Control Arm for a Rare Disease Drug Trial
Our client was developing a new anti-viral drug for a rare, life-threatening viral infection that…
Certara2023 年 4 月 17 日
Using Real World Evidence to Inform Treatment Guidelines
Real-World Evidence (RWE) has become increasingly valuable in informing the development of treatment guidelines for…
Certara2023 年 4 月 5 日
